The biocomplex was validated both in vitro and in vivo and demonstrated to be able to specifically deliver Dox and PTX in MCF-7 MUC1 positive cells and improved efficacy in reducing cell viability and in vivo tumor growth, when compared to similar biocomplexes loaded with single drugs. Here, MUC1 is linked to neoplasm.